Bo Shen

Baiziting Road
Nanjing, 210009, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 110 publications

Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.

Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.

Journal: The New England journal of medicine

Published: July 08, 2026

Architecture Design and Catalytic Activity: Multidimensional Cu@Ag Core-Shell Structures for Hydrogenation of 4-Nitrophenol.

Architecture Design and Catalytic Activity: Multidimensional Cu@Ag Core-Shell Structures for Hydrogenation of 4-Nitrophenol.

Journal: Langmuir : the ACS journal of surfaces and colloids

Published: March 27, 2026

Tumor cell-released autophagosome (TRAP) programs inflammatory CAFs to drive the immune-excluded TIME through C3a.

Tumor cell-released autophagosome (TRAP) programs inflammatory CAFs to drive the immune-excluded TIME through C3a.

Journal: Cellular & molecular immunology

Published: January 21, 2026

Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy.

Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy.

Journal: Cancer biology & medicine

Published: December 10, 2025

Real-world effectiveness and safety of adebrelimab as first-line treatment in patients with extensive-stage small cell lung cancer.

Real-world effectiveness and safety of adebrelimab as first-line treatment in patients with extensive-stage small cell lung cancer.

Journal: Translational lung cancer research

Published: November 06, 2025

SAA restricts T cell mediated anti-tumor immunity by limiting antigen presentation in lung cancer.

SAA restricts T cell mediated anti-tumor immunity by limiting antigen presentation in lung cancer.

Journal: Frontiers in immunology

Published: October 30, 2025

Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study.

Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: October 02, 2025

FN-1501 Synergistically Enhances Almonertinib Efficacy in EGFR-TKI-Resistant Lung Adenocarcinoma through Ferroptosis Induction.

FN-1501 Synergistically Enhances Almonertinib Efficacy in EGFR-TKI-Resistant Lung Adenocarcinoma through Ferroptosis Induction.

Journal: Anti-cancer agents in medicinal chemistry

Published: September 07, 2025

Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM).

Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM).

Journal: Nature communications

Published: August 29, 2025

Histone lactylation-derived TET2 enhanced Arg1-mediated MDSC immunosuppression.

Histone lactylation-derived TET2 enhanced Arg1-mediated MDSC immunosuppression.

Journal: Frontiers in immunology

Published: August 01, 2025

The EP300-Targeting Drug CCS1477 Inhibits the Growth and Development of Diffuse Large B-Cell Lymphoma by Promoting Apoptosis and Mitophagy to Reduce Drug Resistance.

The EP300-Targeting Drug CCS1477 Inhibits the Growth and Development of Diffuse Large B-Cell Lymphoma by Promoting Apoptosis and Mitophagy to Reduce Drug Resistance.

Journal: Anti-cancer agents in medicinal chemistry

Published: July 28, 2025

Histone H4K8 lactylation modulated immunosuppressive properties by promoting FAP transcription and ECM remodeling.

Histone H4K8 lactylation modulated immunosuppressive properties by promoting FAP transcription and ECM remodeling.

Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Published: June 21, 2025

Showing 1-12 of 110

Last Updated: 09/26/2026